11/11/2008 News For: Kaiser Insuranceence RatesAboriginal leaders reject upcoming report on cancer rates downstream of oilsands FORT CHIPEWYAN, Alta. - Aboriginal leaders say they reject an upcoming report on cancer rates among their people who live downstream of Alberta's oilsands. Rivaroxaban Phase II Dose-Ranging Study Demonstrates Encouraging Response Rates in Treatment of Acute Coronary ... Findings from the Phase II ATLAS ACS TIMI 46 study of rivaroxaban, a novel, investigational, oral anticoagulant, were presented today as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008 in New Orleans by C. Michael Gibson, M.D., director of the TIMI Data Coordinating Center, Harvard Medical School. Results from this Phase II study support advancing ... Not enough results were found for the interpreted or exact term. Searching general term for related news. Related general news for: Health InsuranceIntel dives into medical market with home health monitors The world's biggest computer chip maker on Monday dove into the medical market with technology that lets doctors make house calls on patients without being there. |

